CERT · Certara, Inc.
10 customers — 24% of revenue (the year ended December 31, 2025)
“Our ten largest customers accounted for 24% of revenues for the year ended December 31, 2025.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Certara reported Q2 revenue of $93.3 million (up 1%), reaffirmed full-year revenue growth guidance of 0%–4%, but lowered its 2026 adjusted EBITDA margin guide to 29%–31% (from 30%–32%) and adjusted diluted EPS to $0.31–$0.36 due to the May divestiture of the Regulatory and Medical Writing business. The company completed a $100 million share repurchase and authorized an additional $50 million, while appointing a new CCO and citing 27% YoY pipeline growth and software revenue up 4%.
- + Reaffirmed full-year 2026 revenue growth guidance of 0%–4% on a continuing operations basis
- + Pipeline grew 27% year-on-year, expected to translate into revenue growth in 2H 2026
- + Completed $100 million share repurchase and Board authorized an additional $50 million program
- + Reduction in force and operational excellence actions expected to yield ~$13 million in run-rate savings, addressing stranded costs from the divestiture
- − Services revenue declined 3% to $44.5 million and services bookings fell 6% to $47.6 million
- − Full-year 2026 adjusted diluted EPS guidance lowered to $0.31–$0.36 (continuing operations)
- − Adjusted EBITDA declined to $26.2 million from $27.0 million, with margin of 28.1% pressured by stranded divestiture costs
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CERT
this stock
Certara, Inc.
|
$1.41B | +4.4% | +8.7% | — | 18.9% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +27.9% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +38.7% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +51.5% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CERT | +6.5% | +13.6% | +70.1% | +11.0% | +4.4% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +7.2% | +13.5% | +57.9% | +11.6% | -7.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.